Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 12/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14008046 | 1.00 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL16901643 | 1.00 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14008045 | 1.00 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14393866 | 1.00 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14393690 | 1.00 | GAA (0.66) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14197120 | 0.84 | GAA (0.64) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14338232 | 0.84 | GAA (0.64) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14368075 | 0.84 | GAA (0.64) | GAAKDM4EALDH1A1AOC3NPY5R | |
| SCHEMBL14338233 | 0.84 | GAA (0.64) | GAAKDM4EALDH1A1AOC3NPY5R | |
| Methylephedrine SCHEMBL11356628 | 0.83 | KDM4E (0.85) | GAAKDM4EALDH1A1AOC3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102584620-B | The preparation method of alpha-amino ketone derivative | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-09-23 | — | — | CN | claimed |
| US-11857684-B2 | Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof | BAYER HEALTHCARE LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857684-B2 | Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof | BAYER HEALTHCARE LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220151936-A1 | ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF | BAYER HEALTHCARE LLC (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2022103620-A1 | ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF | BAYER HEALTHCARE LLC (US) | 2022-05-19 | — | — | WO | disclosed |
| CN-102584620-B | The preparation method of alpha-amino ketone derivative | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-09-23 | — | — | CN | disclosed |
| CN-102584620-A | Preparation method for alpha-amino ketone derivative | SHANGHAI INST PHARM INDUSTRY | 2012-07-18 | — | — | CN | disclosed |
| US-20080293971-A1 | A Process for the Preparation of R-(-)-N, Alpha-Dimethylphenethylamine (Levmethamfetamine) or S-(+)-N, Alpha-Dimethylphenethylamine (Methamphetamine) from D-Ephendrine, or L-Ephedrine Respectively | EMMELLEN BIOTECH PHARMACEUTICALS LIMITED (IN) | 2008-11-27 | — | — | US | disclosed |
| EP-1828105-B1 | A PROCESS FOR THE PREPARATION OF R-(-)-N, ALPHA-DIMETHYLPHENETHYLAMINE (LEVMETAMFETAMINE) OR S-(+)-N, ALPHA-DIMETHYLPHENETHYLAMINE (METHAMPHETAMINE) FROM d-EPHEDRINE OR L-EPHEDRINE RESPECTIVELY | EMMELLEN BIOTECH PHARMACEUTICA (IN) | 2008-09-03 | — | — | EP | disclosed |
| EP-1828105-A1 | A PROCESS FOR THE PREPARATION OF R-(-)-N, ALPHA-DIMETHYLPHENETHYLAMINE (LEVMETAMFETAMINE) OR S-(+)-N, ALPHA-DIMETHYLPHENETHYLAMINE (METHAMPHETAMINE) FROM d-EPHEDRINE OR L-EPHEDRINE RESPECTIVELY | Emmellen Biotech Pharmaceuticals Limited (IN) | 2007-09-05 | — | — | EP | disclosed |
| US-5750520-A | SELECTIVE THROMBIN INHIBITORS; WOUND HEALING AGENTS | PFIZER INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0822934-A1 | ANTITHROMBOTIC AMIDINOTETRAHYDROPYRIDYLALANINE DERIVATIVES | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-02-11 | — | — | EP | disclosed |
| EP-0728132-B1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LTD (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996033993-A1 | ANTITHROMBOTIC AMIDINOTETRAHYDROPYRIDYLALANINE DERIVATIVES | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1996-10-31 | — | — | WO | disclosed |
| EP-0728132-A1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LTD (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013274-A1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
| US-5192800-A | Hypotensive agents | PFIZER INC. (US) | 1993-03-09 | — | — | US | disclosed |
| EP-0342850-B1 | ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1992-05-20 | — | — | EP | disclosed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | disclosed |
| EP-0342850-A1 | Enantiomeric glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151936-A1 | ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF | PTGDR, PLA2G7, PTGIR | GAA 1463/4885KDM4E 3249/4885ALDH1A1 3274/4885 |
| US-20080293971-A1 | A Process for the Preparation of R-(-)-N, Alpha-Dimethylphenethylamine (Levmethamfetamine) or S-(+)-N, Alpha-Dimethylphenethylamine (Methamphetamine) from D-Ephendrine, or L-Ephedrine Respectively | HNMT, DDT, METTL3 | GAA 1497/4885KDM4E 501/4885ALDH1A1 252/4885 |
| US-11857684-B2 | Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof | PTGDR, PLA2G7, PTGIR | GAA 1463/4885KDM4E 3249/4885ALDH1A1 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.